Xenetic Biosciences, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.
At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets. By integrating these platforms, the company aims to create therapeutics with enhanced efficacy, favorable dosing profiles and better patient compliance.
Xenetic’s lead programs have progressed through preclinical development and early-stage clinical trials, with an emphasis on oncology immunotherapy and enzyme replacement therapies. The company collaborates with academic institutions and industry partners to advance its candidates and to explore new applications of its delivery and targeting technologies. Research and development activities are centralized in the United States, supported by strategic operations in Europe.
Headquartered in Boston, Massachusetts, Xenetic is committed to innovation in biologics and small-molecule therapeutics. Led by a team with deep expertise in protein engineering, drug development and regulatory strategy, the company continues to build a pipeline aimed at improving outcomes for patients with serious and life-threatening conditions. Xenetic Biosciences is publicly traded on the NASDAQ under the ticker XBIO.
AI Generated. May Contain Errors.
